本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：300122 证券简称：智飞生物 公告编号：2024-67 重庆智飞生物制品股份有限公司 第六届董事会第三次会议决议公告 一、董事会会议召开情况 1、本次董事会于 2024 年 12 月 2 日以专人送达和通讯的方式向董事发出通 知。 2、本次会议于 2024 年 12 月 4 日 15:00 在公司会议室以现场结合通讯表决 方式召开。 3、本次会议应出席并参加表决的董事 9 人，实际出席并参加表决的董事 9 人。 4、本次会议由公司董事长蒋仁生先生主持。 5、本次会议的召集、召开和表决程序符合有关法律、行政法规、部门规章、 规范性文件及公司章程的规定。 二、董事会会议审议情况 经过各位董事认真审议，本次会议形成如下决议： 2024 年 12 月 4 日，公司与葛兰素史克生物、葛兰素史克香港（以下合称： "GSK"）签署了《独家经销和联合推广协议补充协议》，优化调整了 2023 年 10 月 8 日签署的原《独家经销和联合推广协议》中约定的重组带状疱疹疫苗采购计 划的相关条款，并进一步拓展了公司在中国大 ...

证券代码：300122 证券简称：智飞生物 公告编号：2024-66 特别提示： 重庆智飞生物制品股份有限公司 ●经友好协商，公司与 GSK 于 2024 年 12 月 4 日签署《独家经销和联合推广协 议补充协议》，主要就此前签署的《独家经销和联合推广协议》中约定的战略合 作期限与采购计划进行调整； 关于与 GSK 优化并调整战略合作的公告 ●本次补充协议的签署深化了公司与 GSK 的战略伙伴关系，促进了双方互助互 信、合作共赢，进一步实现长期、可持续合作。双方将根据市场变化、产品需求， 采购与供应重组带状疱疹疫苗。此外，双方将在中国大陆地区独家探索并积极促 成初步为期 10 年的呼吸道合胞病毒（RSV）疫苗商业化合作； 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 ●采购计划不构成业绩承诺。双方可根据市场情况，友好协商调整采购计划， 调整后以双方书面确认的订单为准，最终对公司经营业绩的影响以公司披露的定 期报告为准； 1、公司与 GSK 进一步深化合作伙伴关系，延长在中国大陆地区的战略合作。 根据原《独家经销和联合推广协议》【原协议详见刊登在中国证监会指 ...

Group 1: Financial Performance and Risks - The company has experienced a significant increase in financial expenses due to large bank loans, leading to a rise in financial risks [2] - The net profit attributable to shareholders has decreased by 103.69% year-on-year, raising concerns among investors [24] - The company is focusing on optimizing its financing structure to maintain a healthy financial status [8] Group 2: Accounts Receivable Management - The company emphasizes risk management for accounts receivable, aiming to reduce bad debts through effective communication and follow-up [2] - Continuous monitoring of accounts receivable is in place to mitigate risks associated with collection [4] Group 3: Research and Development - From 2019 to 2023, the company invested over 4 billion yuan in R&D, with 570 million yuan allocated in the first half of 2024 [8] - The company has 32 ongoing R&D projects, with 18 in clinical trials or registration stages, including a 15-valent pneumonia vaccine [8][20] Group 4: Market Strategy and Product Development - The company is actively promoting HPV vaccine awareness and increasing vaccination rates in collaboration with Merck [15] - Plans are in place to enhance product lines and market strategies to adapt to changing market conditions [14] Group 5: Mergers and Acquisitions - The company is exploring external expansion through mergers and acquisitions to enhance its competitive edge [14] - Integration efforts for the acquisition of Chanan Biotech are ongoing to expand product lines into therapeutic biopharmaceuticals [4] Group 6: Future Outlook - The company anticipates a growth in sales revenue in 2024, particularly with the introduction of the HPV vaccine into the mature market [6] - The establishment of a new branch in Shaanxi is expected to enhance production and R&D capabilities [18]

根据国家医疗保障局、人力资源社会保障部《关于印发<国家基本医疗保险、 工伤保险和生育保险药品目录（2024 年）>》的通知（医保发[2024]33 号，以下 简称"《2024 年国家医保目录》"），重庆智飞生物制品股份有限公司（以下简 称"公司"）全资子公司安徽智飞龙科马生物制药有限公司的重点产品重组结核 杆菌融合蛋白（EC）（商品名：宜卡）纳入《2024 年国家医保目录》。现将相关 情况公告如下： 重组结核杆菌融合蛋白（EC）（商品名：宜卡）适用于结核杆菌感染诊断， 推荐用于 6 月龄及以上婴儿、儿童及 65 周岁以下成人。本品皮试结果不受卡介 苗(BCG)接种的影响，可用于辅助结核病的临床诊断。 重组结核杆菌融合蛋白（EC）（商品名：宜卡）在世界卫生组织（WHO）发 布的最新的结核病（TB）综合指南和结核感染诊断检测操作手册中被推荐用于诊 断结核感染，其具有灵敏度高、特异性高、操作简便等特点，有助于临床快速且 准确地筛查出结核感染人群。截至目前，该产品还正式获得了印度尼西亚药品监 证券代码：300122 证券简称：智飞生物 公告编号：2024-65 重庆智飞生物制品股份有限公司 关于重组结核杆菌融合蛋白( ...

证券代码：300122 证券简称：智飞生物 公告编号：2024-64 重庆智飞生物制品股份有限公司 登录网址：投资者可以登录全景网络平台（https://rs.p5w.net）进入本次 活动专区页面进行交流。 届时，公司高级管理人员将参加本次活动，通过网络在线交流形式，就公司 治理、发展战略、经营状况等投资者所关心的问题，与投资者进行沟通和交流。 衷心感谢投资者对公司的支持，欢迎广大投资者踊跃参与！ 特此公告 重庆智飞生物制品股份有限公司董事会 2024 年 11 月 21 日 1 关于参加"重庆辖区上市公司2024年投资者网上集体接待日"的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 为加强与投资者之间的沟通交流，进一步做好投资者关系管理工作，重庆智 飞生物制品股份有限公司（以下简称"公司"）将参加由重庆证监局指导、重庆 上市公司协会联合深圳市全景网络有限公司举办的重庆辖区上市公司 2024 年投 资者网上集体接待日活动，现将有关事项公告如下： 活动时间：2024 年 11 月 28 日（星期四）15:00-17:00。 ...

Financial Performance - In the first three quarters of 2024, the company achieved operating revenue of 22.786 billion yuan, a decrease of 41.98% compared to the same period last year [1] - The net profit attributable to shareholders, after deducting non-recurring gains and losses, was 2.143 billion yuan, down 66.41% year-on-year [1] - In Q3 2024, the company reported operating revenue of 4.528 billion yuan [1] Market Strategy and Product Development - The company adheres to the mission of "preventing diseases and treating existing ones," focusing on innovation and market expansion despite challenges [1] - Multiple R&D projects have made milestone progress, with a commitment to social benefits as the primary goal and corporate benefits as secondary [2] - The company has increased its R&D expenditure to 696 million yuan this year, ensuring efficient progress of various projects [3] Dividend Policy - The mid-term profit distribution plan involves distributing a cash dividend of 2.00 yuan (tax included) for every 10 shares, with no bonus shares issued [2] - Cumulative cash dividends since the company's listing will reach 7.318 billion yuan, which is 5.11 times the net amount raised during the IPO [2] Inventory and Accounts Receivable Management - As of the end of Q3, the company's inventory balance reached 20.693 billion yuan, primarily due to planned procurement of imported products [4] - Accounts receivable decreased to 21.392 billion yuan, a decline of 20.94% from the beginning of the period, attributed to reduced sales revenue [4] International Strategy - The company is actively pursuing international development strategies and partnerships, responding to global health challenges such as tuberculosis [5] - In October 2024, the company’s self-developed recombinant tuberculosis fusion protein received regulatory approval in Indonesia, a high-burden country for tuberculosis [5] HPV Vaccine Market - Approximately 320 million women aged 9-45 in China are potential candidates for HPV vaccination, with an overall vaccination rate of about 21% since the vaccine's introduction [3] - The company aims to increase public awareness and vaccination rates to contribute to the goal of "accelerating the elimination of cervical cancer" [3]

Financial Performance - Revenue for the third quarter was RMB 4.53 billion, a decrease of 69.46% year-over-year[2] - Net profit attributable to shareholders was RMB -83.7 million, a decrease of 103.69% year-over-year[2] - Total revenue for the current period is 22.79 billion RMB, a decrease from 39.27 billion RMB in the same period last year[22] - Net profit for the quarter was 2.15 billion RMB, a significant decrease from 6.53 billion RMB in the same period last year[23] - Net profit attributable to the parent company is 28.09 billion RMB, slightly up from 27.86 billion RMB at the beginning of the period[21] - Basic earnings per share dropped to 0.8976 RMB from 2.7210 RMB in the same period last year[23] Cash Flow and Liquidity - Operating cash flow was negative RMB 3.06 billion, a decrease of 218.53% year-over-year[9] - Cash and cash equivalents decreased by 1,182.83% to RMB -3.08 billion due to reduced sales collections and increased payments[9] - The company's monetary funds decreased from 6,340,512,228.61 yuan at the beginning of the period to 3,263,949,292.31 yuan at the end of the period[18] - Operating cash flow was negative 3.06 billion RMB, compared to positive 2.59 billion RMB in the previous year[25] - Cash and cash equivalents decreased by 3.08 billion RMB, ending the quarter at 3.26 billion RMB[26] - Cash received from financing activities increased to 10.27 billion RMB, up from 6.12 billion RMB in the previous year[26] Assets and Liabilities - Total assets increased by 6.92% to RMB 53.71 billion compared to the end of the previous year[3] - Total assets increased to 53.71 billion RMB from 50.23 billion RMB at the beginning of the period[19] - Short-term borrowings surged by 228.18% to RMB 8.65 billion due to increased bank credit loans[7] - Short-term borrowings increased to 8.65 billion RMB from 2.64 billion RMB at the beginning of the period[20] - Total liabilities increased to 22.27 billion RMB from 18.73 billion RMB at the beginning of the period[20] Inventory and Receivables - Inventory increased by 130.27% to RMB 20.69 billion due to planned procurement of agency products[6] - Inventory increased significantly to 20.69 billion RMB from 8.99 billion RMB at the beginning of the period[19] - Accounts receivable decreased to 21.39 billion RMB from 27.06 billion RMB at the beginning of the period[19] Government Subsidies and Taxes - Government subsidies decreased by 89.54% to RMB 15.7 million compared to the same period last year[8] - Income tax expenses decreased by 69.94% to RMB 327.3 million due to reduced profit[8] - Cash paid for taxes decreased to 1.84 billion RMB from 2.42 billion RMB in the same period last year[25] Shareholder Information - Jiang Rensheng holds 289,893,375 unrestricted shares, accounting for a significant portion of the company's total shares[13] - Jiang Lingfeng holds 129,600,000 shares, representing 5.41% of the total shares, with 97,200,000 shares under lock-up[12] - Liu Tieying holds 90,000,000 unrestricted shares, accounting for 3.76% of the total shares[12] - Hong Kong Securities Clearing Company Limited holds 68,182,770 unrestricted shares, representing 2.85% of the total shares[12] - The China Industrial and Commercial Bank-E Fund ChiNext ETF holds 30,535,167 shares, accounting for 1.28% of the total shares[12] - The China Construction Bank-E Fund CSI 300 Healthcare ETF holds 18,694,189 shares, representing 0.78% of the total shares[12] - The China Industrial and Commercial Bank-Huatai-PineBridge CSI 300 ETF holds 22,598,407 shares, accounting for 0.94% of the total shares[12] - The total number of restricted shares at the end of the period is 979,483,499, with no shares released during the period[16] Operational Costs and Expenses - Total operating costs for the current period are 19.69 billion RMB, down from 31.15 billion RMB in the same period last year[22] - R&D expenses increased to 695.55 million RMB, up from 648.54 million RMB in the same period last year[22] - Cash paid for employee compensation increased to 1.35 billion RMB from 1.11 billion RMB year-over-year[25] - Credit impairment losses increased to 605.07 million RMB from 567.84 million RMB in the previous year[23] - Asset impairment losses decreased to 26.40 million RMB from 115.14 million RMB year-over-year[23] Revenue and Sales - Revenue from sales of goods and services was 28.43 billion RMB, down from 31.87 billion RMB year-over-year[25] Company Expansion and Operations - The company established a branch in Shaanxi Province to optimize resource allocation and improve operational efficiency[17] R&D and Innovation - R&D expenses and new product development details were not explicitly mentioned in the provided content

证券代码：300122 证券简称：智飞生物 公告编号：2024-58 重庆智飞生物制品股份有限公司 二、董事会会议审议情况 经过各位董事认真审议，本次会议形成如下决议： 1、审议通过了《2024 年第三季度报告》 1、本次董事会于 2024 年 10 月 22 日以电子邮件的方式向董事发出通知。 2、本次会议于 2024 年 10 月 25 日 11:00 在公司会议室以现场结合通讯表决 方式召开。 3、本次会议应出席并参加表决的董事 9 人，实际出席并参加表决的董事 9 人。 4、本次会议由公司董事长蒋仁生先生主持。 5、本次会议的召集、召开和表决程序符合有关法律、行政法规、部门规章、 规范性文件及公司章程的规定。 第六届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 公司《2024 年第三季度报告》的编制程序符合法律、行政法规和中国证监会 的有关规定，报告内容真实、准确、完整地反映了公司的实际经营情况。 本议案已经公司董事会审计委员会审议通过。 《2024 年第三季度报告》于同日发布于中国证监会指定的创业板 ...

流感是由流行性感冒病毒引起的可造成大规模流行的急性呼吸道传染病。流 感的传染性强，可引发肺炎、支气管炎、心肌炎等并发症，也可加重老年人、体 弱者等高危人群的基础疾病。接种流感疫苗是预防流感疾病及流感大爆发最经济、 有效的措施。本次临床试验获得批准的佐剂四价流感疫苗，含公司自主研制的 ZFA02 佐剂，接种后可刺激机体产生针对流感病毒抗原血凝素（HA）体液免疫 和细胞免疫反应，用于预防疫苗相关型别的流感病毒引起的流行性感冒。 二、获得批准的意义 重庆智飞生物制品股份有限公司 关于四价流感病毒裂解疫苗（ZFA02 佐剂） 获得临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆智飞生物制品股份有限公司（以下简称"公司"）于近日获悉，由全资子 公司安徽智飞龙科马生物制药有限公司研发的四价流感病毒裂解疫苗（ZFA02 佐 剂）（以下简称"佐剂四价流感疫苗"）获得国家药品监督管理局药物临床试验批 准通知书（通知书编号：2024LP02408），同意开展预防疫苗相关型别流感病毒引 起的流行性感冒的临床试验。公司将根据临床试验批准通知书的要求，尽快 ...

重庆智飞生物制品股份有限公司 关于流感病毒裂解疫苗申请生产注册获得受理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆智飞生物制品股份有限公司（以下简称"公司"）于近日收到全资子公 司安徽智飞龙科马生物制药有限公司（以下简称"智飞龙科马"）报告，由智飞 龙科马自主研发的流感病毒裂解疫苗申请生产注册获得国家药品监督管理局出 具的《受理通知书》（受理号：CXSS2400114）。现将相关情况公告如下： 一、研发项目简介 流感是由流行性感冒病毒引起的可造成大规模流行的急性呼吸道传染病，传 染性强，可引发肺炎、支气管炎、心肌炎等并发症，可加重老年人、体弱者等高 危人群的基础疾病，增加疾病负担，危害人类健康。接种流感疫苗是预防流感疾 病及流感大爆发最经济、有效的措施。本次生产注册获得受理的流感病毒裂解疫 苗为三价流感疫苗，可刺激机体产生抗流感病毒的免疫力，用于预防疫苗相关型 别的流感病毒引起的流行性感冒。 二、获得受理的意义 截至本公告日，经查询国家药品监督管理局网站，国内有 14 款获批上市的 流感病毒裂解疫苗。若本项目进展顺利，将进一步丰富公司病毒类疫苗 ...